Petit S, Garcion E, Benoit J-P, Menei P
Inserm U646, Angers, France.
Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):547-53. doi: 10.1016/j.neurol.2008.03.015. Epub 2008 Jun 4.
Many arguments support the development of local therapies for malignant gliomas. Simple injections of antimitotic agents into the surgical cavity has been replaced by more sophisticated systems. Tissues can be infused with complex prolonged-release polymeric or lipidic systems with macroscopic, microscopic and now even nanometric particles. But, as for any drug, the developments of these new agents has been long and only very few reach the stage of the clinic trials.
许多论据支持针对恶性胶质瘤开发局部治疗方法。向手术腔简单注射抗有丝分裂药物已被更复杂的系统所取代。可以用具有宏观、微观乃至现在的纳米级颗粒的复杂长效聚合物或脂质系统对组织进行灌注。但是,与任何药物一样,这些新制剂的研发历程漫长,只有极少数能进入临床试验阶段。